Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
Endometrial Cancer, Kidney Cancer, Ovarian Cancer, Pheochromocytoma, Sarcoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Complete staging and treatment planning by a multidisciplinary team of cancer specialists is required to determine the optimal treatment for patients with soft tissue sarcoma. In most cases, a combined modality approach of preoperative radiation therapy (preRT) or postoperative radiation therapy (PORT) is used for treatment, rather than a radical surgical procedure such as amputation. Surgery without PORT may be possible in selected cases. The role of chemotherapy is not well defined.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
There is evidence that favorable clinical outcomes may be associated with referral to a specialized sarcoma treatment center.
Evidence (referral to a specialized sarcoma treatment center):
An analysis of a population-based consecutive series of 375 patients with soft tissue sarcoma in Sweden reported the following results:[1][Level of evidence C2]
Sources: 1 · Level of evidence C2
An analysis of a population-based consecutive series of 375 patients with soft tissue sarcoma in Sweden reported the following results:[1][Level of evidence C2]
The local recurrence rate was 45% (35 of 78 patients) in patients who were not referred.
The local recurrence rate was 24% (24 of 102 patients) in patients who were referred after initial surgery or incisional biopsy.
The local recurrence rate was 18% (36 of 195 patients) in patients who were referred before any surgical procedure.
Local recurrence rates in patients with resected tumors were higher in those who were not referred (for the primary tumor) to the specialized center (P = .0001 for the difference between those not referred vs. those referred before any surgical procedure).
There were no statistically significant differences in death from sarcoma among the groups.
A British study of 260 patients with soft tissue sarcoma diagnosed within a 3-year period reported the following results:[2]
Sources: 2
A British study of 260 patients with soft tissue sarcoma diagnosed within a 3-year period reported the following results:[2]
Thirty-seven percent of the patients had most of their treatment at a specialized center.
The remaining 63% were treated at 38 different hospitals.
The rate of local recurrence was 19% for patients treated at the specialized center.
The rate of local recurrence was 39% for patients treated at the district general hospitals, even though the tumors in these patients were smaller and of lower grade.
The most significant factors affecting survival were tumor grade (high grade vs. low grade) and the depth of the tumor.
Patients treated at the specialized center had a small survival advantage after multivariate analysis.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
| Stage (TNMG Staging Criteria) | Treatment Options | |
|---|---|---|
| T = primary tumor; N = regional lymph node; M = distant metastasis; G = grade. | ||
| Stage I soft tissue sarcoma | Surgery | |
| Surgery with radiation therapy | ||
| High-dose radiation therapy | ||
| Stage II and node-negative stage III soft tissue sarcoma | Surgery | |
| Surgery with radiation therapy | ||
| Radiation therapy and/or chemotherapy followed by surgery | ||
| High-dose radiation therapy | ||
| Advanced stage III (N1) soft tissue sarcoma | Surgery and lymphadenectomy | |
| Surgery with neoadjuvant or adjuvant therapy | ||
| Stage IV soft tissue sarcoma | Chemotherapy | |
| Histology-specific targeted or immunotherapy treatment | ||
| Surgery | ||
| Recurrent soft tissue sarcoma | Surgery with or without radiation therapy | |
| Chemotherapy and targeted therapy | ||
| Immune checkpoint inhibitor therapy (under clinical evaluation) | ||
Sources: TNMG Staging Criteria · Surgery · Surgery with radiation therapy · High-dose radiation therapy · Surgery · Surgery with radiation therapy · Radiation therapy and/or chemotherapy followed by surgery · High-dose radiation therapy · Surgery and lymphadenectomy · Surgery with neoadjuvant or adjuvant therapy · Chemotherapy · Histology-specific targeted or immunotherapy treatment · Surgery · Surgery with or without radiation therapy · Chemotherapy and targeted therapy · Immune checkpoint inhibitor therapy
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Surgical resection is the mainstay of therapy for soft tissue sarcomas.
In some small low-grade tumors of the extremities or trunk, surgery alone can be performed without the use of radiation. Evidence for this approach is limited to single-institution, relatively small case series [3-5] or analysis of outcomes in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program tumor registry.[6] These comparisons suffer from low statistical power and differential evaluability rates that could have introduced bias.[3]
Patient selection factors may vary among surgeons. In general, surgery alone is considered in patients with low-grade tumors of the extremity or superficial trunk that are 5 cm or smaller in diameter (T1) and have microscopically negative surgical margins. In these patients, the rate of long-term local tumor control is about 90%.[7]
Sources: 7
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
When feasible, wide-margin function-sparing surgical excision is the cornerstone of effective treatment for extremity tumors. This may be facilitated by soft tissue reconstructive surgery, which generally permits wider margins than those obtained when the surgical plan involves direct closure of the excision site.[8] Cutting into the tumor mass or shelling out the gross tumor is associated with an elevated risk of local recurrence. Even for high-grade disease, soft tissue sarcomas of the extremities can usually be effectively treated while preserving the limb with combined-modality treatment consisting of preRT or PORT to reduce local recurrence.[9] For more information, see the Radiation Therapy section.
Sources: 8 · 9 · Radiation Therapy
Evidence (amputation vs. limb-sparing surgery):
A retrospective study analyzed a prospective sarcoma database of 649 patients with extremity soft tissue sarcoma. Ninety-two patients underwent amputation, and 557 patients had a limb-sparing procedure. Patients who underwent amputation had large (≥5 cm) high-grade tumors that invaded major vascular or nervous structures.[10]
Sources: 10
A retrospective study analyzed a prospective sarcoma database of 649 patients with extremity soft tissue sarcoma. Ninety-two patients underwent amputation, and 557 patients had a limb-sparing procedure. Patients who underwent amputation had large (≥5 cm) high-grade tumors that invaded major vascular or nervous structures.[10]
The patients who underwent amputation achieved significantly better local control than the patients who had a limb-sparing procedure (P = .007).
However, no survival benefit was demonstrated in the patients selected for amputation (i.e., patients with large high-grade tumors) when compared with patients undergoing a limb-sparing procedure with similar tumors.
Prevention of local recurrence by amputation did not improve survival in this group compared with similar patients undergoing limb-sparing surgery who did develop a local recurrence.
A retrospective study included 769 patients with a high-grade sarcoma of the extremities who underwent a limb-sparing surgery. Eighty-nine patients were treated with neoadjuvant radiation therapy, 315 patients were treated with adjuvant irradiation, and 365 patients were treated with surgery alone.[11]
Sources: 11
A retrospective study included 769 patients with a high-grade sarcoma of the extremities who underwent a limb-sparing surgery. Eighty-nine patients were treated with neoadjuvant radiation therapy, 315 patients were treated with adjuvant irradiation, and 365 patients were treated with surgery alone.[11]
After a mean follow-up of 45 months, 95 local recurrences occurred, resulting in a local recurrence-free survival rate of 83.2% after 5 years and 75.9% after 10 years.
Neoadjuvant radiation therapy provided the best local recurrence-free rate for 5 years (90.0%), but after 10 years (78.3%) adjuvant irradiation resulted in better local control.
Patients treated with neoadjuvant radiation therapy had the highest rate of revision surgery (9.0%), followed by patients who were treated with surgery alone (5.5%) and patients who received adjuvant irradiation (4.4%) (P = .085).
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Local control of high-grade soft tissue sarcomas of the trunk and the head and neck can be achieved with surgery in combination with radiation therapy.[12] Surgery without PORT may be possible in selected patients. A case series was reported from a specialized sarcoma treatment referral center, in which 74 selected patients with primary extremity and trunk tumors 5 cm or smaller were found to have no histological involvement of the surgical margins.[3] These patients were observed without radiation therapy, and the estimated local recurrence rate after 10 years was 11%.[3][Level of evidence C3]
Sources: 12 · 3 · 3 · Level of evidence C3
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Effective treatment of retroperitoneal sarcomas requires removal of all gross disease while sparing adjacent viscera not invaded by tumor. The prognosis for patients with high-grade retroperitoneal sarcomas is less favorable than for patients with tumors at other sites, partly because of the difficulty in completely resecting these tumors and the dose-limiting toxicity of high-dose radiation therapy on visceral organs.[13-16]
Local disease control is crucial in patients with retroperitoneal sarcomas. Disease-specific mortality caused by local recurrence (without synchronous metastasis) was reported in up to 77% of patients with retroperitoneal sarcomas compared with 9% of patients with extremity or trunk sarcomas.[17] An additional consideration in retroperitoneal sarcomas is the extent of surgery.
Sources: 17
Evidence (extended surgical resection):
A series of 382 patients with retroperitoneal sarcoma in a multivariate analysis showed the following results:[18]
Sources: 18
A series of 382 patients with retroperitoneal sarcoma in a multivariate analysis showed the following results:[18]
Patients treated with extended surgical resection had a 3.3-fold lower rate of local recurrence compared with patients who underwent simple complete resection.
Extended surgical resection was not associated with improved survival.
In a follow-up analysis, a 66% overall survival (OS) rate was observed in the extended surgical resection cohort compared with a 48% OS rate in historic controls.[19]
Sources: 19
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
In the setting of distant metastasis, surgery may be associated with long-term disease-free survival (DFS) in patients with pulmonary metastasis and optimal underlying disease biology. This includes patients with a limited number of metastases and slow nodule growth who have undergone or are undergoing complete resection of the primary tumor.[24-26] It is not clear to what degree the favorable outcomes are attributable to the efficacy of surgery or the careful selection of patients based on factors that are associated with less-aggressive disease.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
A patterns-of-care study using SEER data was queried to identify patients undergoing surgery for trunk and extremity soft tissue sarcomas from 2004 to 2009.[27] Of 5,075 patients, 50% received radiation therapy. Radiation therapy was not given as recommended in a significant portion of patients undergoing treatment for soft tissue sarcoma in the United States. Although routine radiation therapy is not recommended for patients with stage I disease, 25% of them still underwent radiation. Even though routine radiation therapy is recommended for patients with stage II and III tumors, only 60% of them underwent radiation. The multivariate analysis identified predictors of radiation therapy efficacy:[27][Level of evidence C2]
Sources: 27 · 27 · Level of evidence C2
Age younger than 50 years (odds ratio [OR], 1.57; 95% confidence interval [CI], 1.28–1.91).
Malignant fibrous histiocytoma histology (OR, 1.47; 95% CI, 1.3–1.92).
T2 disease (OR, 1.88; 95% CI, 1.60–2.20).
High tumor grade (G3) (OR, 6.27; 95% CI, 5.10–7.72).
Patients with stage III soft tissue sarcoma who received radiation therapy showed improved disease-specific survival at 5 years, compared with those who did not receive radiation therapy (68% vs. 46%, P < .001).
Sometimes the initial management of soft tissue sarcoma cannot include surgical excision because the morbidity would be unacceptable, or nearby critical organs make complete resection impossible. In such circumstances, radiation has been used as the primary therapy;[28] however, this must be considered a treatment of last resort. Experience of radiation as the primary therapy is limited to retrospective case series from single centers.[28][Level of evidence C3]
Sources: 28 · 28 · Level of evidence C3
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Radiation plays an important role in limb-sparing therapy. Pre- and postoperative radiation therapy has been shown to decrease the risk of local recurrence. These techniques have not prolonged OS in prospective trials, but they are used to avoid amputation for all but the most locally advanced tumors or in limbs seriously compromised by vascular disease, where acceptable functional preservation is not possible. In the case of external-bean radiation therapy (EBRT), irradiation of the entire limb circumference is avoided to preserve vascular and nerve structures that are critical to retain the function of the limb.
Evidence (PORT):
PORT has been tested in a single-institution randomized trial of 141 patients with extremity sarcomas who were treated with limb-sparing surgery. Patients with high-grade tumors (n = 91) also received adjuvant chemotherapy (five 28-day cycles of doxorubicin and cyclophosphamide). Patients were randomly assigned to receive either radiation therapy (45 Gy to a wide field, plus a tumor-bed boost of 18 Gy over 6–7 weeks) concurrently with chemotherapy (in the case of high-grade tumors) or no radiation.[29][Level of evidence B1]
Sources: 29 · Level of evidence B1
PORT has been tested in a single-institution randomized trial of 141 patients with extremity sarcomas who were treated with limb-sparing surgery. Patients with high-grade tumors (n = 91) also received adjuvant chemotherapy (five 28-day cycles of doxorubicin and cyclophosphamide). Patients were randomly assigned to receive either radiation therapy (45 Gy to a wide field, plus a tumor-bed boost of 18 Gy over 6–7 weeks) concurrently with chemotherapy (in the case of high-grade tumors) or no radiation.[29][Level of evidence B1]
At up to 12 years of follow-up, there was one local recurrence in the 70 patients randomly assigned to receive radiation therapy versus 17 recurrences in the 71 control patients (P = .0001). There was a similar reduction in risk of local recurrence for both high- and low-grade tumors.
There was no difference in OS between the radiation therapy group and the control group.
Global quality of life was similar in the two groups, but the radiation therapy group had substantially worse functional deficits resulting from reduced strength, reduced joint motion, and increased edema.
To limit acute toxicity, smaller fields and lower doses of radiation are generally given with preRT than with PORT. PreRT has been directly compared with PORT for extremity soft tissue sarcomas in a multicenter randomized trial, and no significant difference in local control or OS rates was found.[30-32]
Evidence (preRT vs. PORT):
Though designed to include 266 patients, a trial was stopped after 190 patients were accrued because wound complications in the preRT group had increased. In the first phase of the trial, patients in the preRT group received wide-field radiation therapy of 50 Gy (in 2-Gy fractions). In the second phase of the trial, patients received an additional 16 Gy to 20 Gy to the tumor bed and a 2-cm margin (only if tumor cells were found at the surgical margins). Patients in the PORT group received radiation therapy during both phases of the trial.[30-32]
Though designed to include 266 patients, a trial was stopped after 190 patients were accrued because wound complications in the preRT group had increased. In the first phase of the trial, patients in the preRT group received wide-field radiation therapy of 50 Gy (in 2-Gy fractions). In the second phase of the trial, patients received an additional 16 Gy to 20 Gy to the tumor bed and a 2-cm margin (only if tumor cells were found at the surgical margins). Patients in the PORT group received radiation therapy during both phases of the trial.[30-32]
The wound complication rates were 35% in the preRT group and 17% in the PORT group (P = .01). In addition, limb function at 6 weeks after surgery was worse in the preRT group (P = .01).[30]
Sources: 30
At 5 years, the two groups had similar local control rates (93% for the preRT group vs. 92% for the PORT group) and OS rates (73% for the preRT group vs. 67% for the PORT group; P = .48).[31]
Sources: 31
Of the 129 patients evaluated for limb function at 21 to 27 months after surgery (n = 73 for preRT and n = 56 for PORT), limb function was similar in both groups, but there was a statistical trend for less fibrosis in the preRT group (P = .07).[32]
Sources: 32
Brachytherapy has also been investigated as an adjuvant therapy for soft tissue sarcomas. Although brachytherapy has the possible advantages of convenience and giving less radiation to normal surrounding tissue relative to EBRT, the two treatment strategies have not been directly compared in terms of efficacy or morbidity. However, adjuvant brachytherapy has been compared with surgery without radiation.
Evidence (surgery followed by brachytherapy vs. surgery alone):
In a single-institution trial, 164 patients with sarcomas of the extremity or superficial trunk were randomly assigned during surgery (if all gross tumor could be excised) to receive an iridium Ir 192 implant delivering 42 Gy to 45 Gy over 4 to 6 days (78 patients) or to a control arm of no radiation (86 patients).[33,34] Thirty-four patients in each study arm with high-grade tumors who were believed to be at risk for metastasis received adjuvant doxorubicin-based chemotherapy.[33][Level of evidence B1]
Sources: 33 · 34 · 33 · Level of evidence B1
In a single-institution trial, 164 patients with sarcomas of the extremity or superficial trunk were randomly assigned during surgery (if all gross tumor could be excised) to receive an iridium Ir 192 implant delivering 42 Gy to 45 Gy over 4 to 6 days (78 patients) or to a control arm of no radiation (86 patients).[33,34] Thirty-four patients in each study arm with high-grade tumors who were believed to be at risk for metastasis received adjuvant doxorubicin-based chemotherapy.[33][Level of evidence B1]
With a median follow-up of 76 months, the 5-year actuarial local recurrence rates were 18% in the brachytherapy arm and 31% in the control arm (P = .04). This difference was limited to patients with high-grade tumors.
There was no discernible difference in sarcoma-specific survival rates between the brachytherapy arm (84%) and control arm (81%) (P = .65), and there was no difference in patients with high-grade tumors.
The rates of clinically important wound complications (e.g., the need for operative revision or repeated seroma drainage, wound separation, large hematomas, or purulent infection) were 24% in the brachytherapy arm and 14% in the control arm (P = .13). The wound reoperation rates were 10% in the brachytherapy arm and 0% in the control arm (P = .006).[34]
Sources: 34
Intensity-modulated radiation therapy (IMRT) has been used to deliver preRT or PORT to patients with extremity soft tissue sarcomas to spare the femur, joints, and selected other normal tissues from the full prescription dose, and thus maintain local control while potentially reducing radiation therapy–related morbidity. Initial single-institution reports suggest that high rates of local control with some reduction in morbidity are possible with IMRT.[35,36]
Retrospective comparison of IMRT and 3-dimensional, conformal radiation therapy demonstrated that local recurrence for primary soft tissue sarcomas of the extremity was worse in the non-IMRT group.[37][Level of evidence C3]
Sources: 37 · Level of evidence C3
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Retrospective data support the use of preRT or PORT versus surgery alone to treat retroperitoneal sarcomas.
Evidence (preRT or PORT vs. surgery alone):
Outcomes from a total of 9,068 patients in two case-control studies conducted between 2003 and 2011 were analyzed.[38]The 2,196 patients who received PORT were compared with 2,196 matched controls.The 563 patients who received preRT were compared with 1,126 matched controls.[38]
Outcomes from a total of 9,068 patients in two case-control studies conducted between 2003 and 2011 were analyzed.[38]The 2,196 patients who received PORT were compared with 2,196 matched controls.The 563 patients who received preRT were compared with 1,126 matched controls.[38]
The median OS was 89 months for the patients in the PORT group versus 64 months for the patients who did not receive radiation therapy.
The 5-year survival rate was 60% for the patients in the PORT group and 52% for the patients who did not receive radiation therapy.
The median OS was 110 months for the patients who received preRT versus 66 months for the patients who did not receive radiation therapy.
The 5-year survival rate was 62% for the patients who received preRT versus 54% for the patients who did not receive radiation therapy.
Two small prospective studies explored the role of neoadjuvant radiation therapy in patients with intermediate- or high-grade retroperitoneal sarcomas. In a combined analysis of the 54 patients who underwent R0 resection (resection for cure or complete remission) or R1 resection (resection to microscopic residual tumor) after preRT, the following results were reported:[39]
Sources: 39
Two small prospective studies explored the role of neoadjuvant radiation therapy in patients with intermediate- or high-grade retroperitoneal sarcomas. In a combined analysis of the 54 patients who underwent R0 resection (resection for cure or complete remission) or R1 resection (resection to microscopic residual tumor) after preRT, the following results were reported:[39]
The 5-year local relapse-free survival (RFS) rate was 60%.
The 5-year DFS rate was 60%.
The 5-year OS rate was 61%. The median OS had not been reached (>60 months) at the time of the report.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
The role of adjuvant chemotherapy remains controversial. Any potential benefits should be considered in the context of the short- and long-term toxicities of the chemotherapy regimen.
Several prospective, randomized trials were unable to determine conclusively whether doxorubicin-based adjuvant chemotherapy benefits adults with resectable soft tissue sarcomas. Most of these studies accrued small numbers of patients and did not demonstrate a metastasis-free survival or an OS benefit from adjuvant chemotherapy.[12] There was wide interstudy variability among the reported trials, including differences in therapeutic regimens, drug doses, sample sizes, tumor sites, and tumor histological grades.
Sources: 12
Evidence (doxorubicin-based adjuvant chemotherapy):
A quantitative meta-analysis of updated data from 1,568 individual patients in 14 trials of doxorubicin-based adjuvant chemotherapy was reported. Only a small proportion of patients in this meta-analysis were treated with ifosfamide, an agent with demonstrated activity against soft tissue sarcoma.[40,41][Level of evidence B1] The following results were reported:
Sources: 40 · 41 · Level of evidence B1
A quantitative meta-analysis of updated data from 1,568 individual patients in 14 trials of doxorubicin-based adjuvant chemotherapy was reported. Only a small proportion of patients in this meta-analysis were treated with ifosfamide, an agent with demonstrated activity against soft tissue sarcoma.[40,41][Level of evidence B1] The following results were reported:
An absolute benefit from adjuvant chemotherapy of 6% for local relapse-free interval (95% CI, 1%–10%), 10% for distant relapse-free interval (95% CI, 5%–15%), and 10% for RFS (95% CI, 5%–15%).
No statistically significant OS benefit at 10 years was detected; the absolute difference was 4% (95% CI, -1% to +9%).
A subset analysis suggested that patients with sarcomas of the extremities may have benefited from adjuvant chemotherapy, with a reported 7% absolute OS improvement at 10 years (hazard ratio [HR]death, 0.8; P = .029).[41]
Sources: 41
Subsequent chemotherapy trials were performed using anthracycline and ifosfamide combinations in patients who primarily had extremity or trunk soft tissue sarcomas. The data are conflicting.
Evidence (anthracycline and ifosfamide or cyclophosphamide combinations):
In a small feasibility study, 59 patients with high-risk soft tissue sarcomas (58 of whom had an extremity or the trunk as the primary site) underwent primary resection plus PORT. They were then randomly assigned to observation versus a dose-dense regimen of six 14-day cycles of ifosfamide, dacarbazine (DTIC), and doxorubicin (IFADIC regimen) with granulocyte colony-stimulating factor (G-CSF) bone marrow support.[42]
Sources: 42
In a small feasibility study, 59 patients with high-risk soft tissue sarcomas (58 of whom had an extremity or the trunk as the primary site) underwent primary resection plus PORT. They were then randomly assigned to observation versus a dose-dense regimen of six 14-day cycles of ifosfamide, dacarbazine (DTIC), and doxorubicin (IFADIC regimen) with granulocyte colony-stimulating factor (G-CSF) bone marrow support.[42]
There were no statistically significant differences in OS or RFS. However, the study was severely underpowered.
In a second trial performed by the Italian National Council for Research, high-risk patients were treated with local therapy (wide resection plus preRT or PORT, or amputation as clinically necessary) and were then randomly assigned to observation versus five 21-day cycles of 4-epidoxorubicin (epirubicin) plus ifosfamide (with mesna and G-CSF).[43,44]In summary, the trial was underpowered because it was stopped early, and the promising early results that led to stopping the trial diminished as the trial matured.
In a second trial performed by the Italian National Council for Research, high-risk patients were treated with local therapy (wide resection plus preRT or PORT, or amputation as clinically necessary) and were then randomly assigned to observation versus five 21-day cycles of 4-epidoxorubicin (epirubicin) plus ifosfamide (with mesna and G-CSF).[43,44]In summary, the trial was underpowered because it was stopped early, and the promising early results that led to stopping the trial diminished as the trial matured.
Based on power calculations, the planned study size was 190 patients, but the trial was stopped after 104 patients had been entered because an interim analysis revealed a statistically significant (P = .001) difference in DFS favoring the chemotherapy arm. By the time of the initial peer-reviewed report of the study, the DFS still favored the chemotherapy arm (median DFS of 48 months vs. 16 months), but the P value had risen to .04.[43]
Sources: 43
Although there was no difference in metastasis-free survival at the time of the report, there was an improvement in median OS (75 months for the chemotherapy arm vs. 46 months for the observation arm; P = .03).
At the follow-up report (median follow-up of 89.6 months in a range of 56–119 months), OS differences were no longer statistically significant (58.5% in the chemotherapy arm vs. 43.1% in the observation arm; P = .07).[44]
Sources: 44
The DFS difference had also lost statistical significance (47.2% in the chemotherapy arm vs. 16.0% in the observation arm; P = .09).[44]
Sources: 44
In a third, underpowered, single-center trial, 88 patients with high-risk soft tissue sarcomas (64 with extremity or trunk primary tumors) underwent surgery (with or without radiation) and were then randomly assigned to receive four 21-day cycles of chemotherapy, epirubicin (n = 26) or epirubicin plus ifosfamide (n = 19), versus no adjuvant chemotherapy (n = 43).[45] The trial was closed prematurely because of a slow accrual rate.
Sources: 45
In a third, underpowered, single-center trial, 88 patients with high-risk soft tissue sarcomas (64 with extremity or trunk primary tumors) underwent surgery (with or without radiation) and were then randomly assigned to receive four 21-day cycles of chemotherapy, epirubicin (n = 26) or epirubicin plus ifosfamide (n = 19), versus no adjuvant chemotherapy (n = 43).[45] The trial was closed prematurely because of a slow accrual rate.
After a median follow-up of 94 months, the 5-year DFS rates were 69% in the chemotherapy arm and 44% in the control arm (P = .01).
The 5-year OS rates were 72% in the chemotherapy arm and 47% in the control arm (P = .06).
All the benefit associated with chemotherapy appeared restricted to the 19 patients who received epirubicin plus ifosfamide.
In another underpowered trial, 134 patients with high-risk soft tissue sarcomas (93% with extremity or trunk primary tumors) were randomly assigned to undergo surgical resection (with or without radiation) or to receive three preoperative 21-day cycles of doxorubicin plus ifosfamide.[46] This multicenter trial from the European Organisation for Research and Treatment of Cancer (EORTC) (EORTC-62874) was closed because of slow accrual and results that were not promising enough to warrant continuation of the trial.
Sources: 46 · EORTC-62874
In another underpowered trial, 134 patients with high-risk soft tissue sarcomas (93% with extremity or trunk primary tumors) were randomly assigned to undergo surgical resection (with or without radiation) or to receive three preoperative 21-day cycles of doxorubicin plus ifosfamide.[46] This multicenter trial from the European Organisation for Research and Treatment of Cancer (EORTC) (EORTC-62874) was closed because of slow accrual and results that were not promising enough to warrant continuation of the trial.
With a median follow-up of 7.3 years, the 5-year DFS rates were 52% in the surgery-alone arm and 56% in the chemotherapy-plus-surgery arm (P = .35).
The 5-year OS rates were 64% in the surgery-alone arm and 65% in the chemotherapy-plus-surgery arm (P = .22).
The previous four trials have been combined with the 14 first-generation trials in a trial-level meta-analysis.[47] Of the 18 randomized trials of patients with resectable soft tissue sarcomas, 5 trials used a combination of doxorubicin (50–90 mg/m2 per cycle) plus ifosfamide (1,500–5,000 mg/m2 per cycle). The remaining 13 trials used doxorubicin (50–70 mg/m2 per cycle) alone or with other drugs.[47][Level of evidence A1]
Sources: 47 · 47 · Level of evidence A1
The previous four trials have been combined with the 14 first-generation trials in a trial-level meta-analysis.[47] Of the 18 randomized trials of patients with resectable soft tissue sarcomas, 5 trials used a combination of doxorubicin (50–90 mg/m2 per cycle) plus ifosfamide (1,500–5,000 mg/m2 per cycle). The remaining 13 trials used doxorubicin (50–70 mg/m2 per cycle) alone or with other drugs.[47][Level of evidence A1]
The absolute risk reduction in local recurrence rates associated with any chemotherapy added to local therapy was 4% (95% CI, 0%–7%), and it was 5% (95% CI, 1%–12%) when ifosfamide was combined with doxorubicin.
The absolute reduction in overall mortality was 6% with any chemotherapy (95% CI, 2%–11%; this was a reduction from 46% to 40%), 11% for doxorubicin plus ifosfamide (95% CI, 3%–19%; this was a reduction from 41% to 30%), and 5% for doxorubicin without ifosfamide.
An additional multicenter randomized trial (EORTC-62931 [NCT00002641]) that used adjuvant doxorubicin (75 mg/m2) plus ifosfamide (5,000 mg/m2) was not included in the previous meta-analysis.[48] After local therapy, 351 patients were randomly assigned to five 21-day cycles of adjuvant therapy versus observation. The results of EORTC-62931 differed from those reported in the previous meta-analysis.[47]
Sources: EORTC-62931 · 48 · EORTC-62931 · 47
An additional multicenter randomized trial (EORTC-62931 [NCT00002641]) that used adjuvant doxorubicin (75 mg/m2) plus ifosfamide (5,000 mg/m2) was not included in the previous meta-analysis.[48] After local therapy, 351 patients were randomly assigned to five 21-day cycles of adjuvant therapy versus observation. The results of EORTC-62931 differed from those reported in the previous meta-analysis.[47]
The OS rate did not differ significantly between groups (HR, 0.94; 95% CI, 0.68–1.31; P = .72); neither did the RFS rate (HR, 0.91, 0.67–1.22; P = .51).
The 5-year OS rates were 66.5% (95% CI, 58.8%–73%) in the chemotherapy group and 67.8% (95% CI, 60.3%–74.2%) in the control group.
In a subsequent analysis of pooled individual patient data, the EORTC investigators combined data from this trial (EORTC-62931) with data from their previous trial (EORTC-62771) [49] of adjuvant cyclophosphamide plus doxorubicin plus dacarbazine (CYVADIC), representing the two largest trials of adjuvant therapy for adults with soft tissue sarcoma in the literature (N = 819 patients).[50] [Level of evidence A1];[51]
Sources: EORTC-62931 · EORTC-62771 · 49 · 50 · Level of evidence A1 · 51
In a subsequent analysis of pooled individual patient data, the EORTC investigators combined data from this trial (EORTC-62931) with data from their previous trial (EORTC-62771) [49] of adjuvant cyclophosphamide plus doxorubicin plus dacarbazine (CYVADIC), representing the two largest trials of adjuvant therapy for adults with soft tissue sarcoma in the literature (N = 819 patients).[50] [Level of evidence A1];[51]
Large tumor size, high histological grade, and R1 resection emerged as independent adverse prognostic factors for RFS and OS.
Adjuvant chemotherapy was an independent favorable prognostic factor for RFS but not for OS.
Males and patients older than 40 years had a significantly better RFS in the treatment arms, while adjuvant chemotherapy was associated with a marginally worse OS in females and patients younger than 40 years.
The combined analysis showed no improvement in either RFS or OS associated with adjuvant chemotherapy.
In summary, the impact of adjuvant chemotherapy on survival is still controversial but is likely to be small in absolute magnitude.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
In prospective studies, neoadjuvant chemotherapy with or without radiation therapy has shown response rates of 17% to 32%, 10-year RFS rates of up to 58%, and 10-year OS rates of up to 64%.[46,52-56]
In retrospective studies, neoadjuvant chemotherapy with or without radiation therapy has resulted in DFS rates of 80% to 90% compared with about 60% in historical controls.[57-59]
A combined analysis of the RTOG-9514 study (NCT00002791) of neoadjuvant chemoradiation and the RTOG-0630 study (NCT00589121) of neoadjuvant radiation therapy showed rates of pathological complete response of 27.5% in patients on neoadjuvant chemoradiation and 19.4% in patients on neoadjuvant radiation therapy in 123 evaluable patients. At a median follow-up of more than 5 years, the OS rate was 100% in patients with pathological complete responses; 5-year survival rates were 76.5% (RTOG-9514) and 56.4% (RTOG-0630) for patients who did not achieve pathological complete responses.[60]
Evidence (neoadjuvant histotype-tailored chemotherapy vs. standard chemotherapy):
The phase III ISG-STS1001 study (NCT01710176) enrolled 164 patients with high-risk features (grade 3 tumor or grade 2 tumor with more than 50% necrosis, size ≥5 cm, deep location).[56] Patients were randomly assigned to receive either standard chemotherapy or histotype-tailored chemotherapy for three cycles as listed below:The following results were reported:
Sources: ISG-STS1001 · 56
The phase III ISG-STS1001 study (NCT01710176) enrolled 164 patients with high-risk features (grade 3 tumor or grade 2 tumor with more than 50% necrosis, size ≥5 cm, deep location).[56] Patients were randomly assigned to receive either standard chemotherapy or histotype-tailored chemotherapy for three cycles as listed below:The following results were reported:
Standard chemotherapy (every 21 days):
The phase III ISG-STS1001 study (NCT01710176) enrolled 164 patients with high-risk features (grade 3 tumor or grade 2 tumor with more than 50% necrosis, size ≥5 cm, deep location).[56] Patients were randomly assigned to receive either standard chemotherapy or histotype-tailored chemotherapy for three cycles as listed below:The following results were reported: › Standard chemotherapy (every 21 days):
Epirubicin, 60 mg/m2, on days 1 and 2 plus ifosfamide, 3 g/m2, on days 1, 2, and 3.
The phase III ISG-STS1001 study (NCT01710176) enrolled 164 patients with high-risk features (grade 3 tumor or grade 2 tumor with more than 50% necrosis, size ≥5 cm, deep location).[56] Patients were randomly assigned to receive either standard chemotherapy or histotype-tailored chemotherapy for three cycles as listed below:The following results were reported:
Histotype-tailored chemotherapy:
The phase III ISG-STS1001 study (NCT01710176) enrolled 164 patients with high-risk features (grade 3 tumor or grade 2 tumor with more than 50% necrosis, size ≥5 cm, deep location).[56] Patients were randomly assigned to receive either standard chemotherapy or histotype-tailored chemotherapy for three cycles as listed below:The following results were reported: › Histotype-tailored chemotherapy:
Undifferentiated pleomorphic sarcoma: docetaxel, 75 mg/m2, on day 8 plus gemcitabine, 900 mg/m2, on days 1 and 8 (every 21 days).
Myxoid liposarcoma: trabectedin, 1.3 mg/m2, continuous infusion (every 21 days).
Synovial sarcoma: ifosfamide, 14 g/m2, 14 days of continuous infusion (every 28 days).
Malignant peripheral nerve sheath tumor: ifosfamide, 3 g/m2, on days 1, 2, and 3 plus etoposide, 150 mg/m2, on days 1, 2, and 3 (every 21 days).
Leiomyosarcoma: gemcitabine, 1,800 mg/m2, on day 1 plus dacarbazine, 500 mg/m2, on day 1 (every 14 days).
The phase III ISG-STS1001 study (NCT01710176) enrolled 164 patients with high-risk features (grade 3 tumor or grade 2 tumor with more than 50% necrosis, size ≥5 cm, deep location).[56] Patients were randomly assigned to receive either standard chemotherapy or histotype-tailored chemotherapy for three cycles as listed below:The following results were reported:
With a median follow-up of 12.3 months, the projected RFS rate at 46 months was 62% (95% CI, 48%–77%) for patients who received standard chemotherapy versus 38% (95% CI, 22%–P = .004).
The OS rate was 89% (95% CI, 78%–99%) in the standard chemotherapy group versus 64% (95% CI, 27%–100%) in the histotype-tailored chemotherapy group (P = .034).
Trabectedin for myxoid liposarcoma had outcomes similar to those for the standard chemotherapy group.[56]
Sources: 56
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Anthracyclines remain the first-line class of systemic therapy in managing most locally advanced and metastatic soft tissue sarcoma.[61]
Sources: 61
Other regimens, approved for use as second-line therapy and beyond, include:
Gemcitabine/docetaxel.[62]
Sources: 62
Ifosfamide.
Trabectedin (liposarcoma and leiomyosarcoma).[63]
Sources: 63
Eribulin (liposarcoma).[64]
Sources: 64
Pazopanib.[65]
Sources: 65
Dacarbazine.
Pegylated liposomal (encapsulated) doxorubicin.[66]
Sources: 66
Taxanes or taxane combinations are used for patients with angiosarcomas.
The clinical benefit of adding other drugs to the single-agent doxorubicin regimen is controversial.
In randomized studies, the combination of doxorubicin with ifosfamide has not demonstrated superiority over doxorubicin alone in terms of OS, but adding ifosfamide to doxorubicin may be considered in cases where reaching a better response to treatment, despite more toxicity, is the main treatment goal.[52,67]
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment options for stage I soft tissue sarcoma include:
Sources: stage I soft tissue sarcoma
Surgery.
Sources: Surgery
Surgery with radiation therapy.
Sources: Surgery with radiation therapy
High-dose radiation therapy.
Sources: High-dose radiation therapy
For more information on surgery and radiation therapy, see the Treatment Option Overview for Soft Tissue Sarcoma section.
Sources: surgery · radiation therapy · Treatment Option Overview for Soft Tissue Sarcoma
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Low-grade soft tissue sarcomas have little metastatic potential, but they have a tendency to recur locally. The treatment of choice for patients with early-stage sarcomas (tumors ≤5 cm in diameters) is surgical excision with negative tissue margins (of 1 cm to 2 cm or larger) in all directions.[3-10]
The Mohs surgical technique may be considered as an alternative to wide surgical excision for very rare, small, well-differentiated primary sarcomas of the skin when cosmetic results are important, as margins can be assured with minimal normal tissue removal.[11]
Sources: 11
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Surgical excision with preoperative radiation therapy (preRT) or postoperative radiation therapy (PORT) may be indicated. Radiation therapy decreases the risk of local recurrence but has not been shown to increase overall survival.[12-14]
Options for tumors of the retroperitoneum, trunk, and head and neck include:
Surgical resection with the option of PORT if negative margins cannot be obtained. Wide margins are unusual in these sites, and radiation therapy is usually advocated for trunk and head and neck primary tumor sites.[15]
Sources: 15
PreRT followed by maximal surgical resection. Radiation therapy may be used in sarcomas of the trunk and head and neck to maximize local control when wide surgical margins cannot be obtained.[16]
Sources: 16
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
For unresectable tumors, higher doses of radiation therapy with curative intent may be used.[17] Carefully executed high-dose radiation therapy using a shrinking-field technique may be beneficial in the following cases:[18]
Unresectable tumors.
Resectable tumors with inadequate margins and a high likelihood of residual disease.
A wide resection requires an amputation or the removal of a vital organ.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment options for stage II and node-negative stage III soft tissue sarcoma include:
Sources: stage II · stage III soft tissue sarcoma
Surgery.
Sources: Surgery
Surgery with radiation therapy.
Sources: Surgery with radiation therapy
Radiation therapy and/or chemotherapy followed by surgery.
Sources: Radiation therapy and/or chemotherapy followed by surgery
High-dose radiation therapy.
Sources: High-dose radiation therapy
For more information on surgery, radiation therapy, and chemotherapy, see the Treatment Option Overview for Soft Tissue Sarcoma section.
Sources: surgery · radiation therapy · chemotherapy · Treatment Option Overview for Soft Tissue Sarcoma
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Complete surgical resection (removal of the entire gross tumor) is the most important factor in preventing local recurrence and, in many instances, requires resection of adjacent viscera. Surgical excision with negative tissue margins in all directions is generally restricted to low-grade tumors of the extremities (≤5 cm in diameter) or superficial trunk tumors with microscopically negative surgical margins.[1-5]
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
High-grade localized soft tissue sarcomas have an increased potential for local recurrence and metastasis. For sarcomas of the extremities, local control comparable to that obtained with amputation may be achieved with limb-sparing surgery that involves wide local excision in combination with preoperative radiation therapy (preRT) or postoperative radiation therapy (PORT). Radiation decreases the risk of local recurrence but has not been shown to increase overall survival.[8-11]
A retrospective review that compared surgery with or without preRT for retroperitoneal sarcomas suggested that the addition of preRT was associated with improved local recurrence-free survival, but not disease-free survival.[12]
Sources: 12
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
In some situations, radiation therapy and/or chemotherapy may be used before surgery to convert a marginally resectable tumor to one that can be adequately resected with limb preservation. This treatment may be followed by PORT.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
For unresectable tumors, high-dose radiation therapy may be used, but poor local control is likely to result.[13]
Sources: 13
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment options for advanced stage III (N1) soft tissue sarcoma include:
Sources: stage III (N1) soft tissue sarcoma
Surgery and lymphadenectomy.
Sources: Surgery and lymphadenectomy
Surgery with neoadjuvant or adjuvant therapy.
For more information on surgery, radiation therapy, and chemotherapy, see the Treatment Option Overview for Soft Tissue Sarcoma section.
Sources: surgery · radiation therapy · chemotherapy · Treatment Option Overview for Soft Tissue Sarcoma
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Regional lymph node involvement by soft tissue sarcomas in adults is rare but may occur in some sarcoma types. The sarcoma types that more commonly spread to lymph nodes include:[1]
Sources: 1
High-grade rhabdomyosarcoma.
Vascular sarcomas.
Synovial sarcoma.
High-grade fibrosarcoma.
Clear cell sarcoma.
Epithelioid sarcomas.
Surgical resection and lymphadenectomy with or without postoperative radiation therapy may be indicated for patients with clinically positive lymph nodes.[1]
Sources: 1
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Neoadjuvant chemotherapy with or without radiation therapy or radiation therapy alone may be considered in selected cases where a limb-sparing surgery is advisable and/or there is a high probability of surgical resection with positive margins.[2-7]
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment options for stage IV soft tissue sarcoma include:
Sources: stage IV soft tissue sarcoma
Chemotherapy.
Sources: Chemotherapy
Histology-specific targeted or immunotherapy treatment.
Sources: Histology-specific targeted or immunotherapy treatment
Surgery.
Sources: Surgery
For more information on surgery and chemotherapy, see the Treatment Option Overview for Soft Tissue Sarcoma section.
Sources: surgery · chemotherapy · Treatment Option Overview for Soft Tissue Sarcoma
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Doxorubicin has been the standard systemic therapy in managing metastatic soft tissue sarcoma for several decades.[1-6] Other drugs that may have clinical activity as single agents or in combination with doxorubicin are ifosfamide, other anthracyclines (epirubicin, pegylated liposomal doxorubicin), gemcitabine, trabectedin, eribulin, pazopanib, dacarbazine, and taxanes.[4-10] Despite improved response rates with anthracycline combinations, toxicity is markedly higher without an improvement in overall survival (OS) for patients with soft tissue sarcoma, with the exception of some specific subtypes.[11-13] Thus, sequential use of single agents is the preferred strategy in most clinical settings.
A variety of other regimens have been used, but none have increased OS when compared with doxorubicin alone.[1,2]
There is some evidence that the addition of ifosfamide (with mesna) to doxorubicin increases response rates and progression-free survival (PFS), but it has not been shown to improve OS.[11] There is some evidence that the addition of trabectedin to doxorubicin improves PFS in patients with metastatic or unresectable leiomyosarcoma.[12,13]
Evidence (doxorubicin and ifosfamide vs. doxorubicin alone):
A randomized study (NCT00061984) assessed whether dose intensification of doxorubicin and ifosfamide improved the survival of patients with advanced soft tissue sarcoma compared with doxorubicin alone.[11][Level of evidence A1] In this study, patients were randomly assigned to receive doxorubicin (n = 228) or doxorubicin and ifosfamide (n = 227). The median follow-up was 56 months (interquartile range [IQR], 31–77 months) in the doxorubicin-only group and 59 months (IQR, 36–72 months) in the combination group.
Sources: NCT00061984 · 11 · Level of evidence A1
A randomized study (NCT00061984) assessed whether dose intensification of doxorubicin and ifosfamide improved the survival of patients with advanced soft tissue sarcoma compared with doxorubicin alone.[11][Level of evidence A1] In this study, patients were randomly assigned to receive doxorubicin (n = 228) or doxorubicin and ifosfamide (n = 227). The median follow-up was 56 months (interquartile range [IQR], 31–77 months) in the doxorubicin-only group and 59 months (IQR, 36–72 months) in the combination group.
There was no significant difference in OS between groups: the median OS was 12.8 months (95.5% confidence interval [CI], 10.5–14.3) in the doxorubicin-alone group versus 14.3 months (range, 12.5–16.5) in the doxorubicin and ifosfamide group (hazard ratio [HR], 0.83; 95.5% CI, 0.67–1.03; stratified log-rank test P = .076).
Median PFS was significantly higher for the doxorubicin and ifosfamide group (7.4 months; 95% CI, 6.6–8.3) than for the doxorubicin-alone group (4.6 months; range, 2.9–5.6 ) (HR, 0.74; 95% CI, 0.60–0.90; stratified log-rank test P = .003).
More patients in the doxorubicin and ifosfamide group had an overall response (60 of 227 patients [26%]) than did patients in the doxorubicin-alone group (31 of 228 patients [14%]) (P < .0006).
The most common grade 3 and 4 toxic effects were all more common with doxorubicin and ifosfamide (n = 224) than with doxorubicin alone (n = 223), and included leukopenia (43% vs. 18%), neutropenia (42% vs. 37%), febrile neutropenia (46% vs. 13%), anemia (35% vs. 5%), and thrombocytopenia (33% vs. <1%).
Evidence (doxorubicin and trabectedin vs. doxorubicin alone in leiomyosarcoma):
A randomized, open-label, phase III trial (LMS-04 [NCT02997358]) evaluated the combination of doxorubicin and trabectedin compared with doxorubicin alone for treatment-naïve patients with metastatic and unresectable leiomyosarcoma. Patients were randomly assigned to receive either doxorubicin (at a 20% dose reduction, or 60 mg/m2) with trabectedin (at a 27% dose reduction, or 1.1 mg/m2) for up to six cycles, followed by maintenance trabectedin (at the same dose) or doxorubicin alone (at a standard dose of 75 mg/m2) for up to six cycles. Surgery was allowed in both arms for nonprogressive residual lesions after the completion of six cycles, if judged to be beneficial. A total of 150 patients were enrolled (67 with uterine leiomyosarcoma, 83 with soft tissue leiomyosarcoma); 74 patients received doxorubicin and trabectedin, and 76 patients received doxorubicin alone. The median follow-up was 55 months (IQR, 49–63 months).[13]
A randomized, open-label, phase III trial (LMS-04 [NCT02997358]) evaluated the combination of doxorubicin and trabectedin compared with doxorubicin alone for treatment-naïve patients with metastatic and unresectable leiomyosarcoma. Patients were randomly assigned to receive either doxorubicin (at a 20% dose reduction, or 60 mg/m2) with trabectedin (at a 27% dose reduction, or 1.1 mg/m2) for up to six cycles, followed by maintenance trabectedin (at the same dose) or doxorubicin alone (at a standard dose of 75 mg/m2) for up to six cycles. Surgery was allowed in both arms for nonprogressive residual lesions after the completion of six cycles, if judged to be beneficial. A total of 150 patients were enrolled (67 with uterine leiomyosarcoma, 83 with soft tissue leiomyosarcoma); 74 patients received doxorubicin and trabectedin, and 76 patients received doxorubicin alone. The median follow-up was 55 months (IQR, 49–63 months).[13]
The median OS was significantly higher in the doxorubicin-plus-trabectedin group (33 months), compared with the doxorubicin-alone group (24 months) (HR, 0.65; 95% CI, 0.44–0.95). The 24-month OS rate was 68% (95% CI, 57%–78%) in the combination group and 49% (95% CI, 38%–60%) in the doxorubicin-alone group.[13][Level of evidence A1]
Sources: 13 · Level of evidence A1
The median PFS was significantly higher in the doxorubicin-plus-trabectedin group (12 months), compared with the doxorubicin-alone group (6 months) (HR, 0.37; 95% CI, 0.26–0.53). The 24-month PFS rate was 30% (95% CI, 21%–42%) in the combination group and 3% (95% CI, 1%–9%) in the doxorubicin-alone group.[13][Level of evidence A1]
Sources: 13 · Level of evidence A1
There are some important caveats to consider:
A randomized, open-label, phase III trial (LMS-04 [NCT02997358]) evaluated the combination of doxorubicin and trabectedin compared with doxorubicin alone for treatment-naïve patients with metastatic and unresectable leiomyosarcoma. Patients were randomly assigned to receive either doxorubicin (at a 20% dose reduction, or 60 mg/m2) with trabectedin (at a 27% dose reduction, or 1.1 mg/m2) for up to six cycles, followed by maintenance trabectedin (at the same dose) or doxorubicin alone (at a standard dose of 75 mg/m2) for up to six cycles. Surgery was allowed in both arms for nonprogressive residual lesions after the completion of six cycles, if judged to be beneficial. A total of 150 patients were enrolled (67 with uterine leiomyosarcoma, 83 with soft tissue leiomyosarcoma); 74 patients received doxorubicin and trabectedin, and 76 patients received doxorubicin alone. The median follow-up was 55 months (IQR, 49–63 months).[13] › There are some important caveats to consider:
Only patients in the doxorubicin-plus-trabectedin group without progression after six cycles were eligible to receive maintenance trabectedin. The median number of maintenance cycles of trabectedin received was 10.5. However, a total of 17 patients (23%) in the combination group did not receive maintenance therapy.
In the doxorubicin-alone group, 22% of patients had disease progression during the first six cycles. In the same group, 37% of patients received trabectedin as their second-line treatment, and 23% of patients received trabectedin as third-line therapy or beyond.
Surgery was performed in 20% of patients in the combination group and 8% of patients in the doxorubicin-alone group. This treatment could bias PFS and OS results.
A randomized, open-label, phase III trial (LMS-04 [NCT02997358]) evaluated the combination of doxorubicin and trabectedin compared with doxorubicin alone for treatment-naïve patients with metastatic and unresectable leiomyosarcoma. Patients were randomly assigned to receive either doxorubicin (at a 20% dose reduction, or 60 mg/m2) with trabectedin (at a 27% dose reduction, or 1.1 mg/m2) for up to six cycles, followed by maintenance trabectedin (at the same dose) or doxorubicin alone (at a standard dose of 75 mg/m2) for up to six cycles. Surgery was allowed in both arms for nonprogressive residual lesions after the completion of six cycles, if judged to be beneficial. A total of 150 patients were enrolled (67 with uterine leiomyosarcoma, 83 with soft tissue leiomyosarcoma); 74 patients received doxorubicin and trabectedin, and 76 patients received doxorubicin alone. The median follow-up was 55 months (IQR, 49–63 months).[13]
Grade 3 and 4 adverse events, including neutropenia, anemia, thrombocytopenia, and febrile neutropenia, were more common in the doxorubicin-plus-trabectedin group (97%) than in the doxorubicin-alone group (56%) (P < .001). In addition, grade 3 and 4 liver toxicity was more common in the combination group (46%), compared with the doxorubicin-alone group (3%).
The combination of gemcitabine and docetaxel is used as second-line therapy in treating patients with soft tissue sarcoma. In selected cases, this combination may also be considered as first-line therapy.[5,14] Toxicity is increased with the use of combination chemotherapy. However, no quality-of-life studies have compared the use of single-agent therapy with combination therapy.
Evidence (gemcitabine and docetaxel vs. gemcitabine alone):
A randomized phase II study of 122 patients with soft tissue sarcoma reported the following results:[5][Level of evidence B3]
Sources: 5 · Level of evidence B3
A randomized phase II study of 122 patients with soft tissue sarcoma reported the following results:[5][Level of evidence B3]
The objective response rate was 16% in the gemcitabine and docetaxel group versus 8% in the gemcitabine-alone group.
Median PFS was 6.2 months in the gemcitabine and docetaxel group versus 3.0 months in the gemcitabine-alone group.
Median OS was 17.9 months in the gemcitabine and docetaxel group versus 11.5 months in the gemcitabine-alone group.
In a retrospective series of 133 patients, gemcitabine and docetaxel showed activity in patients with leiomyosarcoma as well as other histologies with an overall response rate of 18.4%.[15]
Sources: 15
Evidence (gemcitabine and docetaxel vs. doxorubicin alone):
The GeDDis trial (ISRCTN07742377) randomly assigned 257 previously untreated patients to receive either gemcitabine and docetaxel or doxorubicin alone.[14]
Sources: ISRCTN07742377 · 14
The GeDDis trial (ISRCTN07742377) randomly assigned 257 previously untreated patients to receive either gemcitabine and docetaxel or doxorubicin alone.[14]
The PFS rate at 24 weeks (46% in both groups) and the primary end point (median PFS, 23.3 weeks vs. 23.7 weeks) were identical in both groups.
This study may have been limited by the relatively low dose of gemcitabine used (675 mg/m2 on days 1 and 8 instead of 900 mg/m2 as in previous trials).
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Although doxorubicin alone has traditionally been considered the standard when comparing new drugs or regimens in the context of phase III clinical trials, some sarcoma subtypes have shown higher sensitivity to specific agents. Table 9 provides examples of specific agents that can be used as frontline treatment for specific subtypes.
Sources: Table 9
| Sarcoma Subtype | Specific Agent |
|---|---|
| ALK = anaplastic lymphoma kinase; mTOR = mammalian target of rapamycin; PEComa = perivascular epithelioid cell tumor; TKI = tyrosine kinase inhibitor. | |
| Alveolar soft-part sarcoma | TKIs, including sunitinib [16] and pazopanib [17] |
| Immunotherapy, including atezolizumab [18] and pembrolizumab [19] | |
| Angiosarcoma | Taxanes [20] |
| Dermatofibrosarcoma protuberans | Imatinib [21,22] |
| Inflammatory myofibroblastic tumor | ALK inhibitors [23] |
| PEComa | mTOR inhibitors [24], including nab-sirolimus [25] |
| NTRK-fusion-associated sarcomas | Larotrectinib [26] |
| Epithelioid sarcoma | Tazemetostat [27] |
| Desmoid tumors | Gamma secretase inhibitors, including nirogacestat [28] |
| TKIs, including sorafenib [29] | |
Sources: 16 · 17 · 18 · 19 · 20 · 21 · 22 · 23 · 24 · 25 · 26 · 27 · 28 · 29
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Evidence (nirogacestat vs. placebo):
A phase III placebo-controlled trial (NCT03785964) included adults with progressing desmoid tumors who had either not received prior therapy or whose disease was refractory to prior therapy. Patients were stratified according to tumor location (intra-abdominal vs. extra-abdominal). Patients were randomly assigned to receive either oral nirogacestat (150 mg twice daily) or placebo (twice daily). A total of 142 patients were assigned (70 to the nirogacestat group and 72 to the placebo group) across 37 sites in the United States, Canada, and Europe. Thirty-seven patients in each group were women of childbearing potential. A total of 110 patients (77%) had previously undergone systemic therapy, radiation therapy, or surgery. The median follow-up was 15.9 months.[28]
Sources: NCT03785964 · 28
A phase III placebo-controlled trial (NCT03785964) included adults with progressing desmoid tumors who had either not received prior therapy or whose disease was refractory to prior therapy. Patients were stratified according to tumor location (intra-abdominal vs. extra-abdominal). Patients were randomly assigned to receive either oral nirogacestat (150 mg twice daily) or placebo (twice daily). A total of 142 patients were assigned (70 to the nirogacestat group and 72 to the placebo group) across 37 sites in the United States, Canada, and Europe. Thirty-seven patients in each group were women of childbearing potential. A total of 110 patients (77%) had previously undergone systemic therapy, radiation therapy, or surgery. The median follow-up was 15.9 months.[28]
The median PFS could not be estimated in the nirogacestat group (due to a low number of events) and was 15.1 months in the placebo group. The risk of disease progression or death was 71% lower in the nirogacestat group (HR, 0.29; 95% CI, 0.15–0.55; P < .001).[28][Level of evidence B1]
Sources: 28 · Level of evidence B1
The objective response rate was 41% in the nirogacestat group and 8% in the placebo group (P < .001). Complete responses occurred in 7% of patients in the nirogacestat group and 0% of patients in the placebo group.
Several patient-reported outcome measures were collected and assessed, including: Compared with patients in the placebo group, patients in the nirogacestat group had significantly improved scores across all assessments (P < .001).
A phase III placebo-controlled trial (NCT03785964) included adults with progressing desmoid tumors who had either not received prior therapy or whose disease was refractory to prior therapy. Patients were stratified according to tumor location (intra-abdominal vs. extra-abdominal). Patients were randomly assigned to receive either oral nirogacestat (150 mg twice daily) or placebo (twice daily). A total of 142 patients were assigned (70 to the nirogacestat group and 72 to the placebo group) across 37 sites in the United States, Canada, and Europe. Thirty-seven patients in each group were women of childbearing potential. A total of 110 patients (77%) had previously undergone systemic therapy, radiation therapy, or surgery. The median follow-up was 15.9 months.[28] › Several patient-reported outcome measures were collected and assessed, including: Compared with patients in the placebo group, patients in the nirogacestat group had significantly improved scores across all assessments (P < .001).
Brief Pain Inventory-Short Form.
GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS) (comprising the Desmoid Tumor Impact Scale physical functioning domain score and the Desmoid Tumor Symptom Scale).
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) scales for global health status-quality of life, physical functioning, and role functioning.
A phase III placebo-controlled trial (NCT03785964) included adults with progressing desmoid tumors who had either not received prior therapy or whose disease was refractory to prior therapy. Patients were stratified according to tumor location (intra-abdominal vs. extra-abdominal). Patients were randomly assigned to receive either oral nirogacestat (150 mg twice daily) or placebo (twice daily). A total of 142 patients were assigned (70 to the nirogacestat group and 72 to the placebo group) across 37 sites in the United States, Canada, and Europe. Thirty-seven patients in each group were women of childbearing potential. A total of 110 patients (77%) had previously undergone systemic therapy, radiation therapy, or surgery. The median follow-up was 15.9 months.[28]
Most (95%) adverse events were grade 1 or 2. The most common events (i.e., affecting >20% of patients) were diarrhea, nausea, fatigue, hypophosphatemia, maculopapular rash, stomatitis, headache, dermatitis acneiform, and vomiting.
Ovarian dysfunction (defined as amenorrhea, premature menopause, menopause, and ovarian failure) occurred in 27 of 36 women (75%) of childbearing potential. Of these 27 women, 20 (74%) had resolution of their adverse event, 5 (19%) had unresolved ovarian dysfunction, and 2 (7%) had an unknown resolution status.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
If the primary tumor is under control, resection of metastatic lung tumors may be associated with long-term disease-free survival in patients with optimal underlying disease biology, such as a limited number of metastases and slow tumor growth.[30-32] It is not clear whether favorable outcomes are attributable to the efficacy of surgery or to patient selection bias.[30-32]
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment of patients with recurrent soft tissue sarcoma depends on the clinical presentation of the disease and previous treatment.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Treatment options for recurrent soft tissue sarcoma include:
Surgery with or without radiation therapy.
Chemotherapy and targeted therapy.
Sources: Chemotherapy and targeted therapy
Trabectedin.
Sources: Trabectedin
Pazopanib.
Sources: Pazopanib
Immune checkpoint inhibitor therapy.
Sources: Immune checkpoint inhibitor therapy
For more information on surgery, radiation therapy, and chemotherapy, see the Treatment Option Overview for Soft Tissue Sarcoma section.
Sources: surgery · radiation therapy · chemotherapy · Treatment Option Overview for Soft Tissue Sarcoma
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Patients who develop a local recurrence can often be treated with local therapy, such as surgical excision plus radiation therapy (after previous minimal therapy) or amputation (after previous aggressive treatment).[1-7] Resection of limited pulmonary metastases may be associated with favorable disease-free survival.[8-10][Level of evidence C3] However, the contribution of selection factors, such as low tumor burden, slow tumor growth, and long disease-free interval, to these favorable outcomes is not known.
Sources: 1 · 7 · 8 · 10 · Level of evidence C3
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Single-agent chemotherapy may be used with other single agents for disease recurrence.[11-16] Agents such as ifosfamide or gemcitabine may be used sequentially at the time of recurrence or progression.[13-15,17][Level of evidence C3] However, as none of these agents have been shown to increase overall survival (OS) in this setting, clinical trials are an appropriate option.
The U.S. Food and Drug Administration (FDA) has approved eribulin, trabectedin, and pazopanib for the treatment of soft tissue sarcomas after failure of a first-line chemotherapy regimen.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Eribulin is a microtubule inhibitor that the FDA approved in 2016 to treat patients with unresectable or metastatic liposarcoma, who previously received anthracycline-containing chemotherapy.
Evidence (eribulin):
The approval of eribulin was based on a phase III, multicenter, randomized study (NCT01327885) of 452 patients with advanced leiomyosarcoma or adipocytic sarcoma who received eribulin (1.4 mg/m2 intravenously [IV] on days 1 and 8 every 3 weeks) versus dacarbazine (850–1,200 mg/m2 IV on day 1 every 3 weeks).[18]
Sources: NCT01327885 · 18
The approval of eribulin was based on a phase III, multicenter, randomized study (NCT01327885) of 452 patients with advanced leiomyosarcoma or adipocytic sarcoma who received eribulin (1.4 mg/m2 intravenously [IV] on days 1 and 8 every 3 weeks) versus dacarbazine (850–1,200 mg/m2 IV on day 1 every 3 weeks).[18]
Although the median OS was 13.5 months for patients who received eribulin versus 11.5 months for patients who received dacarbazine (hazard ratio [HR]death, 0.77; 95% confidence interval [CI], 0.62–0.95), a preplanned subset analysis revealed a median survival of 15.6 months for eribulin versus 8.4 months for dacarbazine in patients with liposarcoma.
Median progression-free survival (PFS) was the same in both groups (2.6 months).
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Trabectedin is an FDA-approved option for second-line treatment of patients with advanced liposarcoma and leiomyosarcoma.
Evidence (trabectedin):
The approval of trabectedin was based on a phase III randomized study (NCT01343277) of 518 patients who received trabectedin (1.5 mg/m2 over 24 hours on day 1 every 21 days) or dacarbazine (1,000 mg/m2 on day 1 every 21 days).[19]
Sources: NCT01343277 · 19
The approval of trabectedin was based on a phase III randomized study (NCT01343277) of 518 patients who received trabectedin (1.5 mg/m2 over 24 hours on day 1 every 21 days) or dacarbazine (1,000 mg/m2 on day 1 every 21 days).[19]
Treatment with trabectedin significantly improved median PFS (4.2 months for patients who received trabectedin vs. 1.5 months for patients who received dacarbazine).
OS, the primary end point, was not statistically different (12.4 months for patients who received trabectedin vs. 12.9 months for patients who received dacarbazine).
Response rates were low in both arms (10% for patients who received trabectedin vs. 7% for patients who received dacarbazine), but clinical benefit (that included both response rates and stable disease) was higher for the trabectedin group (34%) than for the dacarbazine group (19%).
The most common grade 3 and 4 adverse events in the trabectedin group were myelosuppression and transient elevation of liver function test results.
Phase II studies have shown a particularly high response rate to trabectedin in patients with myxoid/round cell liposarcoma, with overall response rates up to 51%, and a 6-month PFS rate of 88%.[20]
Sources: 20
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Pazopanib is a multitargeted, oral, small molecule inhibitor of several tyrosine kinases, including vascular endothelial growth factor receptor-1, -2, and -3; platelet-derived growth factor receptor alpha and beta; and fibroblast growth factor receptor-1, and -3.
Evidence (pazopanib):
The phase III, randomized, double-blind PALETTE study (NCT00753688) from the European Organisation for Research and Treatment of Cancer compared pazopanib (800 mg daily) with placebo in 369 patients with different soft tissue sarcoma subtypes, excluding adipocytic sarcomas and gastrointestinal stromal tumors. Patients were enrolled after disease progression on a first-line anthracycline-based regimen.[21]
The phase III, randomized, double-blind PALETTE study (NCT00753688) from the European Organisation for Research and Treatment of Cancer compared pazopanib (800 mg daily) with placebo in 369 patients with different soft tissue sarcoma subtypes, excluding adipocytic sarcomas and gastrointestinal stromal tumors. Patients were enrolled after disease progression on a first-line anthracycline-based regimen.[21]
The median PFS was 4.6 months for patients who received pazopanib versus 1.6 months for patients who received placebo.
The OS difference was not statistically significant. OS was 12.5 months for patients who received pazopanib versus 10.7 months for patients who received placebo (HR, 0.86; 95% CI, 0.67–1.1).
Overall response rate was 6% for patients who received pazopanib versus 0% for patients who received placebo.
The stability of disease rate was 67% for patients who received pazopanib versus 38% for patients who received placebo.
The most common grade 3 or 4 toxicities in the pazopanib arm were fatigue, hypertension, diarrhea, anorexia, and transient elevation of liver function test results.
Based on these data, pazopanib was approved by the FDA in 2012 for the treatment of patients with soft tissue sarcomas (except the adipocytic subtypes) who have received previous chemotherapy.
After first-line chemotherapy, other agents can be considered, including:
Ifosfamide with or without etoposide.
Dacarbazine.
Temozolomide.
Vinorelbine.
Regorafenib.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Two trials have explored the immune checkpoint inhibitors pembrolizumab, nivolumab, and ipilimumab. Although some activity has been shown in selected soft tissue sarcoma subtypes, the factors that may predict activity to treatment with immune checkpoint inhibitors remain unknown, and their use cannot be routinely recommended.
Evidence (immune checkpoint inhibitors):
The phase II Sarcoma Alliance for Research through Collaboration trial (SARC028 [NCT02301039]) studied treatment with pembrolizumab alone in patients with four soft tissue sarcoma subtypes: undifferentiated pleomorphic sarcoma, synovial sarcoma, leiomyosarcoma, and poorly differentiated or dedifferentiated liposarcoma.[22] Eighty patients were evaluable for response, with half of the patients in the soft tissue sarcoma group and half in the bone sarcoma cohort. Responses were noted in the following subtypes:
The phase II Sarcoma Alliance for Research through Collaboration trial (SARC028 [NCT02301039]) studied treatment with pembrolizumab alone in patients with four soft tissue sarcoma subtypes: undifferentiated pleomorphic sarcoma, synovial sarcoma, leiomyosarcoma, and poorly differentiated or dedifferentiated liposarcoma.[22] Eighty patients were evaluable for response, with half of the patients in the soft tissue sarcoma group and half in the bone sarcoma cohort. Responses were noted in the following subtypes:
Four of 10 patients with undifferentiated pleomorphic sarcoma.
Two of 10 patients with poorly differentiated or dedifferentiated liposarcoma.
One of 10 patients with synovial sarcoma.
Zero of 10 patients with leiomyosarcoma.
The overall response rate was 18%.
The phase II Alliance A091401 study (NCT02500797) randomly assigned patients to receive nivolumab (n = 43) versus nivolumab and ipilimumab (n = 42) for the treatment of different soft tissue sarcomas.[23]
Sources: Alliance A091401 · 23
The phase II Alliance A091401 study (NCT02500797) randomly assigned patients to receive nivolumab (n = 43) versus nivolumab and ipilimumab (n = 42) for the treatment of different soft tissue sarcomas.[23]
Two patients in the nivolumab group had an objective response (5%; one patient with alveolar soft-part sarcoma and one patient with leiomyosarcoma). Six patients in the combination group had an objective response (16%; two patients with leiomyosarcoma, one patient with myxofibrosarcoma, two patients with undifferentiated pleomorphic sarcoma, and one patient with angiosarcoma).
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
The treatment options and prognosis depend on the following:
Sources: prognosis
The type of soft tissue sarcoma.
The size, grade, and stage of the tumor.
Sources: stage
Where the tumor is in the body.
Whether all of the tumor is removed by surgery.
Sources: surgery
The patient's age and general health.
Whether the cancer has recurred (come back).
Sources: recurred
Small, low-grade tumors, especially in the trunk, arms, or legs, are frequently treated with surgery alone. High-grade sarcomas are more difficult to treat and more likely to spread.
Sources: low-grade · High-grade
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
The grade of the tumor describes how abnormal the cancer cells look under a microscope and how quickly the tumor is likely to grow and spread. Low grade, mid grade, and high grade are used to describe soft tissue sarcoma:
Sources: abnormal · microscope · Low grade · high grade
Low grade: In low-grade soft tissue sarcoma, the cancer cells look more like normal cells under a microscope and grow and spread more slowly than in mid-grade and high-grade soft tissue sarcoma.
Mid grade: In mid-grade soft tissue sarcoma, the cancer cells look more abnormal under a microscope and grow and spread more quickly than in low-grade soft tissue sarcoma.
High grade: In high-grade soft tissue sarcoma, the cancer cells look more abnormal under a microscope and grow and spread more quickly than in low-grade and mid-grade soft tissue sarcoma.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
The cancer may come back in the same soft tissue or in other parts of the body.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
There are different types of treatment for patients with soft tissue sarcoma.
The following types of treatment are used:
The following types of treatment are used:
Surgery
Radiation therapy
Chemotherapy
Targeted therapy
Immunotherapy
Treatment for soft tissue sarcoma may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
Different types of treatments are available for patients with soft tissue sarcoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: soft tissue sarcoma · standard · clinical trials · research study · cancer
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
Surgery is the most common treatment for soft tissue sarcoma. It may be the only treatment needed for small, low-grade tumors, especially in the trunk, arms, or legs. The following surgical procedures may be used:
Mohs micrographic surgery: A procedure in which the tumor is cut from the skin in thin layers. During surgery, the edges of the tumor and each layer of tumor removed are viewed through a microscope to check for cancer cells. Layers continue to be removed until no more cancer cells are seen. This type of surgery removes as little normal tissue as possible and is often used where appearance is important, such as on the skin.
Sources: Mohs micrographic surgery · microscope · cells · tissue
Wide local excision: Removal of the tumor along with some normal tissue around it. For tumors of the head, neck, abdomen, and trunk, as little normal tissue as possible is removed.
Sources: Wide local excision · abdomen · trunk
Limb-sparing surgery: Removal of the tumor in an arm or leg without amputation, so the use and appearance of the limb is saved. Radiation therapy or chemotherapy may be given first to shrink the tumor. The tumor is then removed in a wide local excision. Tissue and bone that are removed may be replaced with a graft using tissue and bone taken from another part of the patient's body, or with an implant such as artificial bone.
Sources: Limb-sparing surgery · amputation · Radiation therapy · chemotherapy · graft · implant
Amputation: Surgery to remove part or all of an arm or leg. Amputation is rarely used to treat soft tissue sarcoma.
Lymphadenectomy: A surgical procedure in which lymph nodes are removed and a sample of tissue is checked under a microscope for signs of cancer. This procedure is also called a lymph node dissection.
Sources: Lymphadenectomy · lymph nodes · signs
Radiation therapy or chemotherapy may be given before or after surgery to remove the tumor. When given before surgery, radiation therapy or chemotherapy will make the tumor smaller and reduce the amount of tissue that needs to be removed during surgery. Treatment given before surgery is called neoadjuvant therapy. When given after surgery to remove all of the tumor that can be seen, radiation therapy or chemotherapy will kill any remaining cancer cells. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: neoadjuvant therapy · adjuvant therapy
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Sources: External radiation therapy
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Intensity-modulated radiation therapy (IMRT) is a type of 3-dimensional (3-D) radiation therapy that uses a computer to make pictures of the size and shape of the tumor. Thin beams of radiation of different intensities (strengths) are aimed at the tumor from many angles. This type of external radiation therapy causes less damage to nearby healthy tissue and is less likely to cause dry mouth, trouble swallowing, and damage to the skin.
Sources: Intensity-modulated radiation therapy · 3-dimensional
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.
Sources: Internal radiation therapy · radioactive · seeds · catheters
The way the radiation therapy is given depends on the type and stage of the cancer being treated. External radiation therapy and internal radiation therapy may be used to treat soft tissue sarcoma.
Sources: stage
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).
Sources: drugs · injected · vein · systemic chemotherapy
For more information, see Drugs Approved for Soft Tissue Sarcoma.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. There are different types of targeted therapy. These include:
Sources: Targeted therapy
Tyrosine kinase inhibitor therapy: These inhibitors block signals that cancer cells need to grow and divide. Some tyrosine kinase inhibitors also have angiogenesis inhibitor effects. Tyrosine kinase inhibitors used to treat soft tissue sarcoma include pazopanib, imatinib, sunitinib, and regorafenib. New types of tyrosine kinase inhibitors are being studied, including cediranib and larotrectinib.
Sources: Tyrosine kinase inhibitor · therapy · angiogenesis inhibitor · pazopanib · imatinib · sunitinib · regorafenib · cediranib · larotrectinib
Histone methyltransferase inhibitor therapy: This therapy may help keep cancer cells from growing. Tazemetostat is a type of histone methyltransferase inhibitor therapy used to treat soft tissue sarcoma.
Sources: Histone methyltransferase inhibitor · Tazemetostat
For more information, see Drugs Approved for Soft Tissue Sarcoma.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.
Sources: Immunotherapy · immune system
Immune checkpoint inhibitor therapy is a type of immunotherapy. Some types of immune system cells, such as T cells, and some cancer cells have certain proteins, called checkpoint proteins, on their surface that keep immune responses in check. These checkpoints help keep immune responses from being too strong and sometimes can keep T cells from killing cancer cells. When these checkpoints are blocked, T cells can kill cancer cells better.
Sources: Immune checkpoint inhibitor · immune system · T cells · proteins
Types of immune checkpoint inhibitor therapy include the following:
CTLA-4 inhibitor therapy: CTLA-4 is a protein on the surface of T cells that helps keep the body's immune responses in check. When CTLA-4 attaches to another protein called B7 on a cancer cell, it stops the T cell from killing the cancer cell. CTLA-4 inhibitors attach to CTLA-4 and allow the T cells to kill cancer cells.Ipilimumab is a type of CTLA-4 inhibitor that is being studied to treat soft tissue sarcoma.
Sources: CTLA-4 · Ipilimumab
PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body's immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells.Pembrolizumab and nivolumab are PD-1 inhibitors that are used to treat progressive and recurrent soft tissue sarcoma.
Sources: PD-1 · PD-L1 · Pembrolizumab · nivolumab · progressive · recurrent
For more information, see Drugs Approved for Soft Tissue Sarcoma.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview. To learn about the cancer stages, see Stages of Soft Tissue Sarcoma.
Sources: Treatment Option Overview · Stages of Soft Tissue Sarcoma
Treatment of stage I soft tissue sarcoma may include the following:
Surgery to remove the tumor, such as Mohs microsurgery for small sarcomas of the skin, wide local excision, or limb-sparing surgery.
Sources: Surgery · tumor · Mohs microsurgery · sarcomas · wide local excision · limb-sparing surgery
Radiation therapy before and/or after surgery.
Sources: Radiation therapy
High-dose radiation therapy, for tumors that cannot be removed by surgery.
Sources: High-dose radiation therapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview. To learn about the cancer stages, see Stages of Soft Tissue Sarcoma.
Sources: Treatment Option Overview · Stages of Soft Tissue Sarcoma
Treatment of stage II soft tissue sarcoma and stage III soft tissue sarcoma that has not spread to lymph nodes may include the following:
Sources: lymph nodes
Surgery to remove the tumor, such as wide local excision or limb-sparing surgery.
Sources: Surgery · tumor · wide local excision · limb-sparing surgery
Radiation therapy before or after surgery.
Sources: Radiation therapy
Radiation therapy and/or chemotherapy before limb-sparing surgery. Radiation therapy may also be given after surgery.
Sources: chemotherapy
High-dose radiation therapy for tumors that cannot be removed by surgery.
Sources: High-dose radiation therapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview. To learn about the cancer stages, see Stages of Soft Tissue Sarcoma.
Sources: Treatment Option Overview · Stages of Soft Tissue Sarcoma
Treatment of stage III soft tissue sarcoma that has spread to lymph nodes (advanced) may include the following:
Sources: lymph nodes · advanced
Surgery (wide local excision) with lymphadenectomy. Radiation therapy may also be given after surgery.
Sources: Surgery · wide local excision · lymphadenectomy · Radiation therapy
Surgery with neoadjuvant therapy (chemotherapy or radiation therapy) or adjuvant therapy (radiation therapy).
Sources: neoadjuvant therapy · chemotherapy · radiation therapy · adjuvant therapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview. To learn about the cancer stages, see Stages of Soft Tissue Sarcoma.
Sources: Treatment Option Overview · Stages of Soft Tissue Sarcoma
Treatment of stage IV soft tissue sarcoma may include the following:
Chemotherapy.
Sources: Chemotherapy
Targeted therapy with a tyrosine kinase inhibitor (pazopanib or imatinib).
Sources: Targeted therapy · tyrosine kinase inhibitor · pazopanib · imatinib
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023. Captured 2026-09-09.
For information about the treatments listed below, see Treatment Option Overview. To learn about the cancer stages, see Stages of Soft Tissue Sarcoma.
Sources: Treatment Option Overview · Stages of Soft Tissue Sarcoma
Treatment of recurrent soft tissue sarcoma may include the following:
Surgery (wide local excision) with or without radiation therapy.
Sources: Surgery · wide local excision · radiation therapy
Surgery (amputation; rarely done).
Sources: amputation
Targeted therapy with a tyrosine kinase inhibitor (pazopanib or imatinib).
Sources: Targeted therapy · tyrosine kinase inhibitor · pazopanib · imatinib
Chemotherapy.
Sources: Chemotherapy
A clinical trial of an immune checkpoint inhibitor (pembrolizumab, nivolumab, or ipilimumab).
Sources: clinical trial · immune checkpoint inhibitor · pembrolizumab · nivolumab · ipilimumab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Endometrial Cancer, Kidney Cancer, Ovarian Cancer, Pheochromocytoma, Sarcoma
ClinicalTrials.gov recordSarcoma
ClinicalTrials.gov recordSarcoma
ClinicalTrials.gov recordLymphedema, Musculoskeletal Complications, Radiation Fibrosis, Radiation Toxicity, Sarcoma
ClinicalTrials.gov recordSarcoma, Soft Tissue
ClinicalTrials.gov recordSoft Tissue Sarcoma
ClinicalTrials.gov recordAdvanced Liposarcoma or Leiomyosarcoma
ClinicalTrials.gov recordLocalized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
ClinicalTrials.gov recordSoft Tissue Sarcoma, Bone Sarcoma
ClinicalTrials.gov recordMalignant PEComa
ClinicalTrials.gov recordLocally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic...
ClinicalTrials.gov recordMalignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma,...
ClinicalTrials.gov recordUterine or Soft Tissue Leiomyosarcoma
ClinicalTrials.gov recordMetastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
ClinicalTrials.gov recordDesmoid Tumor, Aggressive Fibromatosis
ClinicalTrials.gov recordDesmoplastic Small Round Cell Tumor
ClinicalTrials.gov recordSynovial Sarcoma
ClinicalTrials.gov recordRecurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma
ClinicalTrials.gov recordAdult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult...
ClinicalTrials.gov recordSynovial Sarcoma
ClinicalTrials.gov recordAdult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Ovarian Sarcoma,...
ClinicalTrials.gov recordSoft Tissue Sarcoma, Fibrous Histiocytoma, Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Synovial Sarcoma
ClinicalTrials.gov recordSarcoma
ClinicalTrials.gov recordLiposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma
ClinicalTrials.gov recordSoft Tissue Sarcoma, Mesothelioma
ClinicalTrials.gov recordAdult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Rhabdomyosarcoma, Dermatofibrosarcoma Protuberans, Endometrial Stromal...
ClinicalTrials.gov recordSarcoma
ClinicalTrials.gov recordSarcoma, Leiomyosarcoma, Malignant Fibrous, Histiocytoma, Angiosarcoma
ClinicalTrials.gov recordSarcoma
ClinicalTrials.gov recordAdult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult...
ClinicalTrials.gov recordRecurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
ClinicalTrials.gov recordAdvanced Cancers, Sarcoma
ClinicalTrials.gov recordSarcoma
ClinicalTrials.gov recordSarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
ClinicalTrials.gov recordAdult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult...
ClinicalTrials.gov recordBone Cancer, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Recurrent...
ClinicalTrials.gov recordRecurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
ClinicalTrials.gov recordMyxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma, Recurrent Liposarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent...
ClinicalTrials.gov recordSoft Tissue Sarcoma
ClinicalTrials.gov recordSarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Myxofibrosarcoma, Angiosarcoma, Fibrosarcoma,...
ClinicalTrials.gov recordHigh Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma,...
ClinicalTrials.gov recordAdvanced and/or Metastatic Sarcoma
ClinicalTrials.gov recordSarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma
ClinicalTrials.gov recordMetastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine...
ClinicalTrials.gov recordLocally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Unresectable...
ClinicalTrials.gov recordAdult Fibrosarcoma
Chemotherapy for advanced disease
Bone Sarcoma
Fibrosarcoma
High Grade Sarcoma
Histiocytic Sarcoma
Adjuvant chemotherapy for clinically localized tumors
Metastatic disease
Treatment of Recurrent Soft Tissue Sarcoma
Soft Tissue Sarcoma
Spindle Cell Sarcoma
Treatment of Stage I Soft Tissue Sarcoma
Treatment of Stage II and Node-Negative Stage III Soft Tissue Sarcoma
Treatment of Advanced Stage III (N1) Soft Tissue Sarcoma
Treatment of Stage IV Soft Tissue Sarcoma
1.2 Soft Tissue Sarcoma VOTRIENT is indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary...
DailyMed labelDoxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary...
DailyMed labelDoxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary...
DailyMed labelINDICATIONS AND USAGE The intra-articular or soft tissue administration of KENALOG-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient...
DailyMed labelINDICATIONS AND USAGE The intra-articular or soft tissue administration of KENALOG-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient...
DailyMed labelINDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for...
DailyMed labelINDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for...
DailyMed labelINDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for...
DailyMed labelINDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as...
DailyMed labelINDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for...
DailyMed labelINDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as...
DailyMed labelINDICATIONS AND USAGE: NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP...
DailyMed labelOGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment. OGSIVEO is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment....
DailyMed label1.1 Kaposi’s Sarcoma PANRETIN GEL is indicated for topical treatment of cutaneous lesions in adults with AIDS related Kaposi’s sarcoma (KS). Limitations of Use: PANRETIN GEL is not indicated when systemic anti-KS therapy is required...
DailyMed labelTECELRA is indicated for the treatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or...
DailyMed labelVOTRIENT is a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). ( 1.1 ) advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy...
DailyMed label